The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program
Open Access
- 27 April 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-8
Abstract
Surveillance, Epidemiology, and End Results (SEER) public research database does not include chemotherapy data due to concerns for incomplete ascertainment. To compensate for perceived lack of data quality many researchers use SEER-Medicare linked data, limiting studies to persons over age 65. We sought to determine current SEER ascertainment of chemotherapy receipt in two relatively large SEER registries compared to patient-reported receipt and to assess patterns of under-ascertainment. In 2011–14, we surveyed patients with Stage III colorectal cancer reported to the Georgia and Metropolitan Detroit SEER registries. 1301/1909 eligible patients responded (68% response rate). Survey responses regarding treatment and sociodemographic factors were merged with SEER data. We compared patient-reported chemotherapy receipt with SEER recorded chemotherapy receipt. We estimated multivariable regression models to assess associations of under-ascertainment in SEER. Eighty-five percent of patients reported chemotherapy receipt. Among those, 10% (n = 104) were under-ascertained in SEER (coded as not receiving chemotherapy). In unadjusted analyses, under-ascertainment was more common for older patients (11.8% age 76+ vs. < 9% for all other ages, p = 0.01) and varied with SEER registries (10.2% Detroit vs. 6.8% Georgia; p = 0.04). On multivariable analyses, chemotherapy under-ascertainment did not vary significantly by any patient attributes. We found a 10% rate of under-ascertainment of adjuvant chemotherapy for resected, stage III colorectal cancer in two SEER registries. Chemotherapy under-ascertainment did not disproportionately affect any patient subgroups. Use of SEER data from select registries is an important resource for researchers investigating contemporary chemotherapy receipt and outcomes.Keywords
Funding Information
- American Cancer Society (Research Scholar Grant # 11-097-01-CPHPS)
- National Institutes of Health (T32CA009672-25)
- National Cancer Institute (K07CA196752-01)
This publication has 43 references indexed in Scilit:
- Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal CancerClinical Colorectal Cancer, 2013
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal CancerJournal of Clinical Oncology, 2012
- Comparison of adverse events during 5‐fluorouracil versus 5‐fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancerCancer, 2012
- Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon CancerJNCI: Journal of the National Cancer Institute, 2012
- Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry dataCancer, 2011
- Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysisEuropean Journal of Cancer, 2010
- Comparison of Commission on Cancer–Approved and –Nonapproved Hospitals in the United States: Implications for Studies That Use the National Cancer Data BaseJournal of Clinical Oncology, 2009
- Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancerBreast Cancer Research and Treatment, 2009
- Explaining Black–White Differences in Receipt of Recommended Colon Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon CarcinomaNew England Journal of Medicine, 1990